Securities code: Maider Medical Industry Equipment Co.Ltd(688310) securities abbreviation: Maider Medical Industry Equipment Co.Ltd(688310) Announcement No.: 2022017 Maider Medical Industry Equipment Co.Ltd(688310)
Supplementary announcement on investment and establishment of wholly-owned subsidiaries and development of new businesses
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Important risk tips:
Up to now, Zhejiang maideshun Medical Co., Ltd. (hereinafter referred to as the “wholly-owned subsidiary”) is still in the preparatory stage. This investment is for the development of contact lens test line. Subsequently, the scale and progress of mass production investment will be determined according to the verification of the test line, and the corresponding procedures will be performed according to the regulations. The wholly-owned subsidiary still needs to go through the relevant procedures of industrial and commercial registration, has not carried out any substantive business and has not signed any agreement. The future production and operation of the wholly-owned subsidiary is not clear. Due to the impact of uncertain factors such as macroeconomic and industrial policy changes and market competition in the future operation and management process, there is a risk that the expansion of new business is less than expected, and the impact on the future performance of the company is uncertain.
The R & D of contact lens business is mainly composed of material formula, injection molding, printing, liquid injection, curing, hydration, material supply, testing, assembly, packaging and other technologies. The company’s existing R & D system and technology process platform for medical consumables intelligent equipment can be used and further expanded in the R & D and production of contact lenses, such as injection molding, printing, liquid injection, curing, hydration, feeding, testing, assembly, packaging and other technologies. At present, the company does not have material formulation technology. In terms of developing contact lens business, there is a risk of not having complete technology and product R & D failure.
Contact lenses belong to the third category of medical device industry, which needs the approval of relevant competent departments, and there is a risk of failure to obtain relevant qualifications.
The company will pay close attention to the establishment of wholly-owned subsidiaries and the follow-up progress of new businesses, actively prevent and respond to various risks that may be faced in the follow-up process, and timely fulfill the obligation of information disclosure in strict accordance with the requirements of relevant laws, regulations and normative documents. Please invest rationally and pay attention to investment risks.
In order to optimize the business layout of Maider Medical Industry Equipment Co.Ltd(688310) (hereinafter referred to as “the company”) and further improve its market competitiveness, the company decided to intervene in the field of contact lens manufacturing by making full use of the company’s unique advantages in intelligent equipment and industrialization process on the basis of doing a good job in its main business according to the future development strategic plan, and plans to establish a wholly-owned subsidiary with a registered capital of 10 million yuan. For details, please refer to the company’s disclosure on Shanghai Stock Exchange (www.sse. Com. CN.) on May 18, 2022 Announcement of Maider Medical Industry Equipment Co.Ltd(688310) on investment and establishment of wholly-owned subsidiaries (Announcement No.: 2022016).
In order to facilitate investors to further understand relevant information, the relevant contents of the above announcement on investment in the establishment of wholly-owned subsidiaries and the development of new businesses are supplemented as follows:
1、 Basic information of new business
(I) new business type
The company plans to set up a wholly-owned subsidiary with its own capital of 10 million yuan to carry out contact lens business and develop contact lens test line. The scale and progress of subsequent mass production investment will be determined according to the sample verification of the test line, so as to provide R & D, manufacturing and services for various contact lens brands.
(II) industry situation of new business
Corneal contact lens is used to correct vision by directly adhering to the tear layer of the cornea. Some lenses also have special functions. It belongs to the third category of medical device industry, mainly divided into soft and hard corneal contact lenses. Contact lenses are soft corneal contact lenses, which can be divided into daily polishing, weekly polishing, monthly polishing, quarterly polishing, semi annual polishing and annual polishing according to the service cycle; It can be divided into transparent contact lenses and color contact lenses according to whether they are colored or not. With the development of China’s economy, the expansion of the population covered by contact lenses such as China’s myopic population, the improvement of people’s quality of life, and the promotion of the Internet and social media, people’s demand for eye health and eye beautification is increasing. In addition, the development standardization and stricter supervision of the contact lens industry have promoted the improvement of China’s contact lens penetration rate, and then promoted the expansion of China’s contact lens market.
“Qingshan capital 2020 China FMCG early investment opportunity report” mentioned that the contact lens market has increased from several billion five years ago to nearly 20 billion, with an annual consumption of 1.8 billion films, accounting for more than half of online consumption. Offline films are mainly transparent, and online color films are favored. In the overall market, color films currently account for about 20%. The contact lens industry is developing rapidly and has a broad market prospect.
(III) management of new business
After the establishment of this wholly-owned subsidiary, it will be included in the scope of the company’s consolidated statements, and the actual controller of the company will not change.
Operation and management: the company will make overall planning for the technology research and development, business channels and industrial integration of the wholly-owned subsidiary, give full play to the synergy between the company’s businesses, realize the complementary advantages between the company and the wholly-owned subsidiary’s businesses, broaden the company’s business scope and market field, and finally realize the implementation of the company’s future development strategy and promote the long-term development of the company.
Financial management: the finance of the wholly-owned subsidiary is fully managed by the company.
Organizational structure: the company will introduce personnel from relevant industries and cooperate with the existing management team to carry out professional operation and management of the wholly-owned subsidiary.
(IV) review procedures
According to the relevant provisions of the Listing Rules of Shanghai Stock Exchange, the rules of procedure of the board of directors and the articles of association of the company, the investment to establish a wholly-owned subsidiary and carry out new business has been deliberated and approved at the general manager’s office meeting, and the independent directors of the company have expressed their independent opinions clearly agreed on the matter. The matter is within the approval authority of the general manager’s office meeting of the company and does not need to be submitted to the board of directors Deliberation at the general meeting of shareholders.
(V) approval of new business
The registration of wholly-owned subsidiaries needs to be approved by relevant competent authorities. The contact lens business needs to apply for the corresponding administrative license and apply for the corresponding license and qualification to the relevant competent department.
2、 Analysis on the rationality and necessity of developing new business
(I) reasons for launching new business
The company’s new business is to make full use of its unique advantages in intelligent equipment and industrialization technology on the basis of doing a good job in its main business, further optimize the business layout and expand the market field, which is in line with the company’s future development strategic plan and conducive to the realization of the company’s long-term goals.
(II) background of new business
The contact lens market continues to expand with broad market prospects. China’s contact lens industry is developing rapidly, but at the same time, there are still problems such as limited production capacity. The company is a leading enterprise of medical consumables and intelligent equipment in China. Its main business is the R & D, production and sales of medical consumables and intelligent equipment.
The company has the compound competitiveness of technical process, regulations and automation of medical consumables products. It has formed a comprehensive research and development system integrating eight modules, including regulations plus process verification, mechanics, machinery, electricity, software, vision, optics and materials science, covering technical process platforms such as material supply, gluing, welding, testing, assembly, winding packaging, transmission, film forming, liquid injection and software control, The existing R & D system and technology process platform can be used and further expanded in the R & D and production of contact lenses.
(III) rationality of new business
Contact lens business mainly includes product R & D, license acquisition, manufacturing and sales.
Product R & D is mainly composed of material formula, injection molding, printing, liquid injection, curing, hydration, feeding, testing, assembly, packaging and other technologies. The company’s existing R & D system and technology process platform for medical consumables intelligent equipment can be used and further expanded in the R & D and production of contact lenses, such as injection molding, printing, liquid injection, curing, hydration, feeding, testing, assembly, packaging and other technologies. In terms of material formula, the company has no ready-made technology to match, and plans to introduce corresponding technology.
In terms of license acquisition, the company has professional and technical personnel who are specially responsible for the relevant work of registration certificate and production license.
In terms of manufacturing, the company has the ability to provide complete sets of mass production solutions for medical consumables enterprises, including but not limited to equipment, software, molds, production process improvement, etc. In the process of cooperation with medical consumables manufacturers for many years, it has rich medical device industrialization capacity. The company has the advantages of expanding production and controlling cost in expanding the contact lens market.
In terms of sales, the company has not established a sales system and team for new business, and will introduce relevant professionals according to the sample verification of the test line.
To sum up, there is a certain correlation and synergy between the contact lens business and the company’s existing R & D and manufacturing.
(IV) preparation of the company
The company has demonstrated the feasibility of the new business and made plans in terms of technical reserve, talent reserve, business expansion and capital arrangement of the new business. The new business can make full use of the existing resource advantages of the company for layout.
Technical reserve: the company is currently preparing to develop contact lens test lines. The specific arrangements are as follows: 1) the R & D teams of the company and its subsidiaries develop relevant technologies and design test lines by themselves; 2) The company introduces relevant technology and equipment.
Talent reserve: the company has reserved technical talents in injection molding, printing, liquid injection, solidification, hydration, material supply, testing, assembly, packaging and license acquisition in the field of medical automation, and will accelerate the introduction of more relevant professionals through multiple channels after the establishment of a wholly-owned subsidiary.
Business development: after the successful research and development of new business products, the company will set up a special sales team for new business and actively explore the market.
Capital arrangement: the investment amount of this new business is 10 million yuan, accounting for 1.14% of the company’s total assets audited in the latest period. It is mainly used for the investment of the new business test line. All the funds come from the company’s own funds and will not cause capital pressure on the development of other businesses of the company.
(V) next step plan for developing new business
After the establishment of the wholly-owned subsidiary, a contact lens test line will be established in Taizhou. The company will determine the scale and progress of subsequent mass production investment according to the sample verification of the test line, and provide contact lens R & D, manufacturing and services for all contact lens brands. The company plans to complete the test line in 2023, obtain relevant qualifications in 2024 and realize mass production in 2025.
Based on the attitude of being responsible to the majority of investors, the company will legally and legally perform the corresponding procedures, promote various matters and disclose the relevant progress in time.
3、 Opinions of independent directors
In order to optimize the company’s business layout and further improve its market competitiveness, the company decided to intervene in the field of contact lens manufacturing by making full use of its unique advantages in intelligent equipment and industrialized technology on the basis of doing a good job in its main business according to the future development strategic plan. The deliberation procedures for the establishment of a wholly-owned subsidiary and the development of new business in this investment comply with the relevant provisions of laws, regulations, normative documents such as the Listing Rules of shares on the science and Innovation Board of Shanghai Stock Exchange and the articles of association. This investment uses the company’s own funds, which will not have an adverse impact on the company’s financial and operating conditions, and there is no damage to the interests of the company, its shareholders, especially small and medium-sized shareholders.
In conclusion, the independent directors of the company unanimously agreed to invest in the establishment of a wholly-owned subsidiary and carry out new business.
4、 Impact on Listed Companies
(I) impact on the company’s production and operation
This investment to establish a wholly-owned subsidiary and carry out new business is based on the actual needs of the company’s development, which is conducive to optimizing the company’s business layout, promoting the gradual implementation of the company’s long-term strategic plan, further improving the company’s comprehensive competitiveness and actively promoting the sustainable development of the company. After the establishment of a wholly-owned subsidiary, it will be included in the scope of the company’s consolidated statements, and the scope of the company’s consolidated statements will be changed.
(II) impact on the company’s financial situation and operating results
This investment uses the company’s own funds and the investment amount is small. At present, it will not have an adverse impact on the company’s financial and operating conditions. In the future, the follow-up investment will be determined with the follow-up development, and there is no damage to the company and shareholders. The future production and operation of the wholly-owned subsidiary is not clear. Due to the impact of uncertain factors such as macroeconomic and industrial policy changes and market competition in the future operation and management process, there is a risk that the expansion of new business is less than expected, and the impact on the future performance of the company is uncertain.
(III) there is no related party transaction and horizontal competition in the investment and establishment of subsidiaries and the development of new business.
5、 Risk tips for developing new business
(I) up to now, the wholly-owned subsidiary is still in the preparatory stage. This investment is for the development of contact lens test line. Subsequently, the scale and progress of mass production investment will be determined according to the verification of the test line, and the corresponding procedures will be performed according to the regulations. The wholly-owned subsidiary still needs to go through the relevant procedures of industrial and commercial registration, has not carried out any substantive business and has not signed any agreement. The future production and operation of the wholly-owned subsidiary is not clear. Due to the impact of uncertain factors such as macroeconomic and industrial policy changes and market competition in the future operation and management process, there is a risk that the expansion of new business is less than expected, and the impact on the future performance of the company is uncertain. (II) the R & D of contact lens business is mainly composed of material formulation, injection molding, printing, liquid injection, curing, hydration, feeding, testing, assembly, packaging and other technologies. The company’s existing R & D system and technology process platform for medical consumables intelligent equipment can be used and further expanded in the R & D and production of contact lenses, such as injection molding, printing, liquid injection, curing, hydration, feeding, testing, assembly, packaging and other technologies. At present, the company does not have material formulation technology. In terms of developing contact lens business, there is a risk of not having complete technology and product R & D failure.
(III) contact lenses belong to class III medical device industry, which needs the approval of relevant competent departments, and there is a risk of failure to obtain relevant qualifications.
(IV) the company will pay close attention to the establishment of wholly-owned subsidiaries and the follow-up progress of new business, actively prevent and respond to various risks that may be faced in the follow-up process, and timely fulfill the obligation of information disclosure in strict accordance with the requirements of relevant laws, regulations and normative documents. Please invest rationally and pay attention to investment risks. 6、 Online announcement attachment
Independent opinions of Maider Medical Industry Equipment Co.Ltd(688310) independent directors on investment and establishment of wholly-owned subsidiaries and development of new businesses
It is hereby announced.
Maider Medical Industry Equipment Co.Ltd(688310) board of directors may 20, 2022
